BridgeBio Pharma (FRA:2CL) Future 3-5Y EPS without NRI Growth Rate : 48.13 (As of Apr. 14, 2025)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, BridgeBio Pharma's Future 3-5Y EPS without NRI Growth Rate is 48.13.

Competitive Comparison of BridgeBio Pharma's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, BridgeBio Pharma's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

BridgeBio Pharma (FRA:2CL) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

BridgeBio Pharma Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines